Ellicott City, M.D., June 8, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year relationship with Center Point Clinical Services, a specialty service provider working to improve critical factors in successful clinical trials, including patient satisfaction, retention, and compliance. Center Point will participate as a Global Impact Partner (GIP) and align with 30 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
“Center Point’s commitment to focus on the enhancement of pivotal facets of clinical trials lays the foundation for a strong relationship with SCRS, and therefore clinical research sites globally,” comments Christine Pierre, SCRS President. “SCRS is proud to welcome them to our community, and commends them for their dedication to promoting site sustainability across the clinical research enterprise.”
“Center Point is pleased to join SCRS and to share in its mission to create a unified voice for the clinical research community,” said Gerald Finken, CEO, Center Point. “At Center Point, we strive to truly listen to our patients and to work with sites to deliver the best possible care. Serving as a Global Impact Partner with SCRS and clinical sites will provide us with crucial new perspectives to better understand the needs of our patients.”
As a Global Impact Partner, Center Point will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.